HOME > COMMENTARY
COMMENTARY
-
Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
-
Battle over Off-Year Price Revision Now Heading for Political Settlement
December 13, 2024
-
Drug Price Gap Hits Record Low, Did Distribution Guidelines Play Any Role?
December 10, 2024
-
Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
December 2, 2024
-
MOF Stands Pat with Off-Year Revisions despite Change in Politics, Does this Hint at Govt’s Reform Directions?
November 27, 2024
-
With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
Survey Hints LLP New Coverage Rule Could Push Generic Switches for Cancer Drugs, Pediatric Meds
October 8, 2024
-
LLP Info Might Become Inaccessible If New Coverage Rule Speeds Up Exit
September 10, 2024
-
Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
-
How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
-
Analysis: All Eyes Riveted on FY2024 Drug Price Survey for Off-Year Revision
August 6, 2024
-
Lively Debate on Generic Industry Revamp Underway, All Eyes on Consortium Model
July 12, 2024
-
Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
-
Japan Employees Shaken by Teva’s Divestment Plan, Soft Landing Wanted on Supply Front
June 4, 2024
-
Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
April 19, 2024
-
With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?
March 12, 2024
-
Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
-
Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
